Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × tislelizumab × Head & Neck × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3 Gastrointestinal 3 Other hematologic neoplasm 1 Head & Neck 1 Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 15 Head and Neck Neoplasms 10 Nasopharyngeal Carcinoma 8 Stomach Neoplasms 2 Sarcoma 2 Neoplasm Metastasis 2 Nasopharyngeal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Testicular Germ Cell Tumor 1 Small Cell Lung Carcinoma 1 Recurrence 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Mesothelioma 1 Melanoma 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Bile Duct Neoplasms 1

Interventions

Cetuximab 13 Gemcitabine 9 Cisplatin 9 pembrolizumab 8 Paclitaxel 7 Nivolumab 6 durvalumab 5 Docetaxel 5 toripalimab 4 Carboplatin 4 Valproic Acid 3 Fluorouracil 3 Capecitabine 3 tremelimumab 2 spartalizumab 2 nimotuzumab 2 irinotecan sucrosofate 2 cemiplimab 2 S 1 (combination) 2 Radiotherapy 2 Radiation 2 Methotrexate 2 Ipilimumab 2 Injections 2 Immune Checkpoint Inhibitors 2 Biopsy 2 18-O-demethylcervinomycin A2 2 vinflunine 1 tranilast 1 tislelizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03924986 2025-01-31

RATIONALE-309

BeiGene

Phase 3 Completed

263 enrolled 19 charts

Nasopharyngeal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡